Cardiovascular Diseases

July 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...

A meta-analysis of randomized controlled trials presented at the American College of Cardiology’s Annual Scientific Session suggests RNA therapeutics reduce mortality and cardiac failure risk in...

The FDA approval provides physicians with a once-daily oral PCSK9 inhibitor option to reduce LDL-C in adults with high cholesterol, including those with heterozygous familial hypercholesterolemia.

In this expert interview, Deepak L. Bhatt, MD, MPH discusses guideline-based and emerging strategies for reducing recurrent ischemic stroke risk. From dietary interventions and blood pressure control to...

The FDA approved Baxfendy as an adjunctive treatment to lower blood pressure in adults with hypertension not adequately controlled on other antihypertensive medications.

In a post hoc analysis of the SURPASS-CVOT randomized clinical trial, researchers found that tirzepatide was associated with fewer cardiorenal events than dulaglutide in high-risk type 2 diabetes.

A post-hoc analysis presented at the American College of Cariology’s Annual Scientific Session suggests that maintaining functional stability, measured by 6-minute walk distance, is associated with lower...

New guideline recommendations from the ACC/AHA and 9 partner organizations prioritize earlier treatment, refined atherosclerotic cardiovascular disease risk prediction, and broader use of lipid biomarkers...

In a post-hoc analysis of ATTR-ACT, investigators examined whether baseline National Amyloidosis Center (NAC) stage influences long-term mortality, cardiovascular outcomes, and health status in patients...

A new cost-effectiveness modeling study evaluates whether coronary artery calcium scoring can refine cardiovascular risk stratification and help identify obese patients most likely to derive clinical and...